BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Source :: GlobeNewswire. September 5, 2024
Publication Year :: 2024
Abstract: E stimated 23 million annual agitation episodes in the at-home setting [sup. 1-3 ] No FDA-approved therapies in the at-home setting for acute treatment of agitation associated with bipolar disorders [...]

Subjects :: Bipolar disorder -- Drug therapy
Dexmedetomidine
Drug approval
Clinical trials
Banking, finance and accounting industries
Business
Igalmi (Medication)

Tools